In this regard, the SMO antagonist molecules, SANT, possess the ability to modulate the Hh pathway in BCC tumors, affecting the expression of its genetic targets such as PTCH1 or its final effectors such as GLI-1 [96]. This evidence concerns the gene PTCH1 and skin basal cell carcinoma.